MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
5.48
+0.33
+6.41%
Pre Market: 5.62 +0.14 +2.55% 04:17 06/29 EDT
OPEN
5.17
PREV CLOSE
5.15
HIGH
5.51
LOW
5.16
VOLUME
3
TURNOVER
0
52 WEEK HIGH
7.18
52 WEEK LOW
1.850
MARKET CAP
897.86M
P/E (TTM)
-4.5084
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANNX last week (0615-0619)?
Weekly Report · 06/22 10:28
Annexon Enters Oversold Territory (ANNX)
NASDAQ · 06/16 21:32
Annexon grants new hires options for 705,000 shares at $4.64 each
PUBT · 06/16 20:05
ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/16 20:05
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 06/16 15:05
Weekly Report: what happened at ANNX last week (0608-0612)?
Weekly Report · 06/15 10:29
Annexon Stockholders Approve Directors, Compensation and Share Increase
TipRanks · 06/12 22:27
Annexon shareholders approve charter amendment to boost authorized common shares to 500 million
PUBT · 06/12 20:17
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.